Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen (OKG-0303) for Acute Infectious Conjunctivitis

Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. To view the full announcement, including...

2026-10-06 9:28 AM EDT